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Variants in ELL2 influencing immunoglobulin levels
associate with multiple myeloma
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Multiple myeloma (MM) is characterized by an uninhibited, clonal growth of plasma cells.
While first-degree relatives of patients with MM show an increased risk of MM, the genetic
basis of inherited MM susceptibility is incompletely understood. Here we report a genome-
wide association study in the Nordic region identifying a novel MM risk locus at ELL2
(rs56219066T; odds ratio (OR)¼ 1.25; P¼9.6 10 10). This gene encodes a stoichiome-
trically limiting component of the super-elongation complex that drives secretory-specific
immunoglobulin mRNA production and transcriptional regulation in plasma cells. We find that
the MM risk allele harbours a Thr298Ala missense variant in an ELL2 domain required for
transcription elongation. Consistent with a hypomorphic effect, we find that the MM risk
allele also associates with reduced levels of immunoglobulin A (IgA) and G (IgG) in healthy
subjects (P¼ 8.6 10 9 and P¼ 6.4 10 3, respectively) and, potentially, with an
increased risk of bacterial meningitis (OR¼ 1.30; P¼0.0024).
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M
ultiple myeloma (MM) is characterized by an un-
inhibited, clonal growth of plasma cells in the bone
marrow, producing a monoclonal immunoglobulin
(‘M protein’) that can be detected in peripheral blood1.
According to the International Myeloma Working Group
criteria, MM is defined by 410% monoclonal plasma cells in
the bone marrow or 43 gM protein per 100ml plasma.
Characteristic symptoms include calcium elevation, renal
insufficiency, anaemia and lytic bone lesions or osteoporosis.
While survival can be extended, MM remains an incurable and
fatal disease2. It is preceded by monoclonal gammopathy of
unknown significance (MGUS)3,4, a common condition (3% of
Z50 year olds)5 defined as a clonal growth of plasma cells that
does not yet satisfy the criteria for MM, but progresses to MM at
a rate of B1% per year.
Since the 1970s, several authors have reported families with
multiple cases of MM, including pedigrees suggesting Mendelian
inheritance6,7. This century, systematic family-based studies,
including in population-based registries, confirmed that first-
degree relatives of patients with MM and MGUS have 2–4 times
higher risk for MM, and a higher risk of certain other
malignancies8–12. These data support the existence of MM risk
alleles. Recent genome-wide association studies have identified
eight common sequence variants that associate with MM, and
account for an estimated 13% of the familial risk13–15.
The molecular basis of inherited MM susceptibility is thus
incompletely understood.
Here we report a genome-wide association study aimed at
identifying DNA sequence variants that predispose for MM in
Nordic populations. We identify a novel risk locus at the
ELL2 gene at 5q31 that encodes a key component of the super-
elongation complex (SEC) that drives secretory-specific Ig mRNA
production and transcriptional regulation in plasma cells. We also
identify a promising association with the TOM1-HMGXB4 locus
at 22q13. We find that the ELL2 MM risk allele harbours a
Thr298Ala missense variant in an ELL2 domain required for
transcription elongation. Consistent with a hypomorphic effect,
we find that the MM risk allele also associates with reduced levels
of IgA and IgG in healthy subjects and, potentially, with an
increased risk of bacterial meningitis.
Results
Genome-wide association study. To identify MM risk loci,
we carried out a genome-wide association study based on one
case–control data set from Sweden and Norway, and one from
Iceland (Table 1). For the Swedish–Norwegian data set, variants
identified by the 1,000 Genomes consortium were imputed into
genotype data generated on Illumina single-nucleotide poly-
morphism (SNP) microarrays. For the Icelandic data set, variants
were identified by whole-genome sequencing of 2,636 Ice-
landers16, and imputed into 104,220 Icelanders genotyped with
Illumina SNP chips17,18. Using the Icelandic genealogy, we
additionally calculated genotype probabilities for 294,212 relatives
of the chip-typed individuals16.
We performed association testing in the Swedish–Norwegian
and Icelandic data sets, and combined the results for 12.1 million
variants that passed quality filtering. Two versions of the
Icelandic case–control data were used for meta-analysis: one
with MM patients only, and one that was expanded with non-
IgM MGUS patients to increase power (Table 1). The latter is
motivated because MM evolves from MGUS3,19, relatives of
MGUS patients have increased MM risk9,12 and known MM risk
alleles tend to associate with MGUS11. We replicated all known
MM risk loci in both meta-analyses (Supplementary Fig. 1 and
Supplementary Table 1; refs 13–15). Quantile–quantile analysis
showed minimal P value inflation (genomic inflation factor
l¼ 1.005–1.020; Supplementary Fig. 2).
Seven loci associated with MM or MMþMGUS at
Po5 10 8 (calculated using logistic regression as described
in Methods section). These included four known MM risk loci
(Fig. 1a and Supplementary Table 1; refs 14,15) and three
previously unknown loci at 5q15 (ELL2), 5q31 (ARHGAP26) and
22q13 (HMGXB4-TOM1; Supplementary Table 2). Inclusion of
the Icelandic MGUS cases strengthened the associations with
5q15 and 5q31. The signals at 5q15 (rs56219066; risk allele
frequency (RAF) 71.1–73.2%) and 22q13 (rs138740; RAF
36.4–41.5%) were represented by common variants with
moderate effects (odds ratio (OR)¼ 1.20–1.39; Fig. 1a,b and
Table 2), whereas the 5q31 signal (rs74735889; RAFB0.3%) was
represented by an imputed rare variant that lost significance
(OR¼ 1.69; logistic regression P¼ 0.014) when genotyped
directly and was not investigated further. Examining the
expression patterns of ELL2, TOM1 and HMGXB4 across
different types of blood cells, we noted that ELL2 and TOM1
are preferentially expressed in normal and malignant plasma
cells (Fig. 1c). Conditional analysis did not reveal any
underlying independent association signals at the ELL2 or
HMGXB4-TOM1 loci.
To validate the 5q15 and 22q13 loci, we genotyped an
additional 586 MM cases and 2,111 controls from Sweden and
Denmark for rs56219066 and rs138740 (Table 1). The rs56219066
SNP replicated in these samples (logistic regression P¼ 0.0046)
and reached genome-wide significance under Bonferroni correc-
tion when the discovery and replication sets were combined
(meta-analysis P¼ 9.6 10 10; Table 2). While rs138740 did not
replicate, it remained borderline significant (meta-analysis P¼ 5.7
 10 8) when the discovery and replication sets were combined
and we observed effects in the same direction as in the meta-
analysis (OR¼ 1.04–1.08; Table 2). Further validation in larger
data sets is needed to confirm the 22q13 locus.
ELL2 regulates RNA processing in plasma cells. The association
with 5q15 was captured by numerous markers in strong linkage
disequilibrium distributed across a B40-kb haplotype block in
ELL2 (elongation factor, RNA polymerase II, 2; previously eleven-
nineteen lysine-rich leukaemia gene 2) (Fig. 1b). This gene
encodes a stoichiometrically limiting component of the SEC20,
which mediates rapid gene induction by suppressing transient
pausing of RNA polymerase II activity along the DNA21.
Strikingly, ELL2 and the SEC play an important role in the
differentiation of mature B cells into plasma cells22,23. In mature
and memory B cells, which express ELL2 at a low level, IGH-
mRNA is translated to membrane-bound Ig. In plasma cells,
ELL2 is highly expressed and helps RNA polymerase II find a
promoter-proximal weak poly(A)-site that is essentially hidden in
B cells. This causes IGH-mRNA to be translated to secreted Ig at a
high rate24,25. B cell-lineage ELL2 conditional knockout mice
exhibit curtailed humoral responses to immunization, reduced
numbers of plasma cells in the spleen and fewer antibody-
producing cells in the bone marrow. Plasma cells isolated from
these mice show a paucity of secreted IgH and a distended
endoplasmic reticulum26. Silencing of ELL2 in mouse
plasmacytoma cell lines using RNA interference decreases the
ratio of secreted versus membrane-encoding Ighg2b transcripts27.
RNA sequencing studies suggest that, in addition to the IGH-
mRNA, ELL2 influences the processing of B12% of transcripts
expressed in plasma cells, including those of the plasma cell
survival receptor Tnfrsf17 (B-cell maturation antigen
(BCMA))22,26 and the MYC oncogene28.
To characterize the ELL2 risk allele, we analysed SNP and
gene expression profiles from peripheral blood (eight data sets
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Table 1 | Study populations.
N Per cent male Age at diagnosis (years±s.d.) Genotyping method
Discovery samples
Sweden and Norway
Cases 1,714 57.1% 67.5±11.4 Illumina OmniExpress-Exome1
Controls 10,391 51.5% — Illumina OmniExpress1
Iceland (MM)
Cases 480 47.9% 71.2±10.0 Illumina microarrays (n¼ 174); familially imputed (n¼ 306)2
Controls 212,164 48.9% — Illumina microarrays (n¼82,742); familially imputed (n¼ 129,422)2
Iceland (MMþMGUS)
Cases 731 49.5% 71.0±12.4 Illumina microarrays (n¼ 332); familially imputed (n¼ 399)2
Controls 283,999 48.8% — Illumina microarrays (n¼90,568); familially imputed (n¼ 193,431)2
Replication samples
Sweden
Cases 223 — — Selected SNPs
Controls 1,285 — — Selected SNPs
Denmark
Cases 363 — — Selected SNPs
Controls 826 — — Selected SNPs
MGUS, monoclonal gammopathy of unknown significance; MM, multiple myeloma; SNP, single-nucleotide polymorphism.
1Imputed using whole-genome sequence data from 1,000 Genomes.
2Imputed using whole-genome sequence data from 2,636 Icelanders.
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Figure 1 | Identification of ELL2 at 5q15 as a novel MM risk locus and HMGXB4-TOM1 at 22q13 as a candidate MM risk locus. (a) Manhattan plot for
the meta-analysis of the Swedish-Norwegian and Icelandic MM data sets for 12.1 million SNPs that passed quality filtering. Seven loci showed association
with MM or MMþMGUS at meta-analysis Po5 108, including four known MM risk loci (pink) and three previously unknown loci at 5q15 (ELL2),
5q35 (ARHGAP26) and 22q13 (HMGXB4 and TOM1) (red). The x axis indicates genomic position of the SNPs. The y axis indicates the –log10 of the
combined P values. The dotted line indicates the threshold for genome-wide significance of meta-analysis Po5 108. The results shown were obtained
with the MMþMGUS version of the Icelandic data. Similar results were obtained with the MM version (not shown). (b) Regional association plots of the
novel risk locus at ELL2 and the tentative risk locus at HMGXB4-TOM1. Positions and P values of SNPs indicated on the x and y axes, respectively. Degree of
linkage disequilibrium with sentinel SNPs indicated in shades of red. Blue background curves indicate meiotic recombination rates. The signal at ARHGAP26
was represented by an imputed rare variant that lost significance when genotyped directly, and was not investigated further. (c) Expression of ELL2,
TOM1 and HMGXB4 in 20 different types of blood cells (Affymetrix microarrays). ELL2 and TOM1 are preferentially expressed in plasma cells.
BASO, basophils; BCELL, B cells; CMP, common myeloid progenitors; EOS, eosinophils; ERY, erythroid progenitors; GMP, granulocyte–monocyte
progenitors; HSCs, haematopoietic stem cells; MEGA, megakaryocytes; MEP, megakaryocyte–erythrocyte progenitors; MONO, monocytes;
NEU, neutrophils; NK, natural killer cells; PC, CD138þ plasma cells; PRE-B, pre-B cells; TCELL, T cells.
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totalling 9,087 samples) and lymphoblastoid cell lines (two
data sets totalling 1,188 samples). We did not detect any risk
allele-associated effect on ELL2 expression (not shown). Because
we did not have access to expression data from plasma cells from
genotyped individuals, we could not exclude a plasma cell-specific
effect on ELL2 expression. Among the associated variants,
however, we identified a Thr298Ala missense variant in ELL2
exon 7 (rs3815768) in tight linkage disequilibrium (D0/r2¼ 1.00/
0.957) with the sentinel SNP rs56219066 in intron 4 (Fig. 2a). The
missense variant is located at the end of a ELL2 domain required
for transcription elongation29.
The ELL2 risk allele associates with decreased IgA and IgG.
Because of the recent mouse studies implicating ELL2 in the
production of secreted Igs, we tested for associations with blood
Table 2 | Association of sequence variants in or near ELL2 and TOM1.
Populations EAF MM MMþMGUS
OR (95% CI) P value OR (95% CI) P value
ELL2—rs56219066-T
Discovery
Sweden/Norway 0.732 1.20 (1.11–1.32) 3.8 10 5 1.20 (1.11–1.32) 3.8 10 5
Iceland 0.711 1.39 (1.17–1.64) 1.1 104 1.32 (1.15–1.51) 3.9 10 5
Combined 1.23 (1.14–1.33) 6.5 10 8 1.23 (1.15–1.33) 1.4 108
Replication
Denmark (363/826) 0.732 1.28 (1.04–1.57) 0.017 1.28 (1.04–1.57) 0.017
Sweden (223/1285) 0.735 1.30 (1.03–1.64) 0.030 1.30 (1.03–1.64) 0.030
Combined 1.29 (1.08–1.54) 0.0046 1.29 (1.08–1.54) 0.0046
Combined discovery and replication 1.25 (1.16–1.34) 9.6 10 10 1.24 (1.16–1.33) 2.2 10 10
TOM1—rs138740-C
Discovery
Sweden/Norway 0.364 1.20 (1.11–1.30) 2.4 10 6 1.20 (1.11–1.30) 2.4 10 6
Iceland 0.415 1.26 (1.09–1.46) 0.0017 1.15 (1.03–1.30) 0.015
Combined 1.22 (1.13–1.30) 1.7 10 8 1.19 (1.11–1.27) 1.3 10 7
Replication
Denmark (352/815) 0.360 1.08 (0.90–1.30) 0.39 1.08 (0.90–1.30) 0.39
Sweden (235/1285) 0.364 1.04 (0.85–1.26) 0.72 1.04 (0.85–1.26) 0.72
Combined 1.06 (0.93–1.21) 0.38 1.06 (0.93–1.21) 0.38
Combined discovery and replication 1.18 (1.11–1.25) 5.7 108 1.16 (1.10–1.23) 2.7 10 7
Abbreviations: CI, confidence interval; EAF, effect allele frequency; MGUS, monoclonal gammopathy of unknown significance; MM, multiple myeloma; OR, odds ratio.
Association results for ELL2 rs56219066 and TOM1 rs138740 in the discovery samples from Sweden, Iceland and Norway and in the replication samples from Sweden and Denmark. Logistic regression
and meta-analysis P values indicated.
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Figure 2 | The ELL2 MM risk allele harbours a Thr298Ala missense variant, and the sentinel SNP rs56219066 is associated with reduced Ig levels.
(a) Schematic representation of the ELL2 gene showing the location of the sentinel SNP rs56219066 in intron 4 and the correlated variant rs3815768 in
exon 7, which causes a Thr298Ala substitution in an ELL2 domain required for transcription elongation. (b) We analysed blood IgA, IgG and IgM levels from
24,279, 21,981 and 20,413 Icelandic individuals without MM or MGUS. We found a significant association between IgA and IgG levels and the
ELL2 risk allele (log-linear regression P values shown). Compared with rs56219066C homozygotes, rs56219066T heterozygotes and homozygotes show
5.2 and 10.1% lower IgA and 2.6 and 5.1% lower IgG, respectively. We observed similar effects for IgA and IgG in an independent set of 1,012 Swedish blood
donors (Supplementary Fig. 3). Boxes indicate medians and the first and third quartiles. Whiskers indicate first and third quartiles 1.5 times the interquartile
range or the minimum/maximum values. Notches indicate confidence intervals around the median. NS, not significant.
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Ig levels in 20,413–24,279 Icelanders without MM or MGUS. Risk
allele carriers showed lower IgA (log-linear regression P¼ 8.6
 10 9) and IgG levels (log-linear regression P¼ 6.4 10 3;
Fig. 2b). The ELL2 haplotype associating with IgA and IgG
levels was identical to the haplotype associating with MM
(Fig. 3). Compared with rs56219066C homozygotes, rs56219066T
heterozygotes and homozygotes showed 5.2 and 10.1% lower IgA
and 2.6 and 5.1% lower IgG, respectively (Fig. 2b). We observed
similar effects in an independent set of 1,012 Swedish blood
donors (Supplementary Fig. 3). The risk allele does not associate
with IgM levels. These results, together with the reduced Ig levels
in the ELL2 conditional knockout mice26, suggest that the MM
risk variant reduces, rather than enhances, the function of ELL2
in plasma cells.
The ELL2 risk allele associates with bacterial meningitis.
Finally, to test whether the ELL2 risk allele affects the risk of other
diseases and traits, we screened deCODE’s databases harbouring
about 400 independent and uncorrelated diseases and quantita-
tive traits. While we did not find any association with other
B-lymphoid proliferative or malignant diseases apart from MGUS
(OR¼ 1.19; logistic regression P¼ 0.0018), we observed associa-
tions between rs56219066T and lower total serum protein levels
(n¼ 20,100; log-linear regression P¼ 0.0014; b¼  0.035) as
previously reported for rs3777200 in ELL2 (D0/r2¼ 1.00/0.96
with rs56219066; ref. 30), and an increased risk of bacterial
meningitis (n¼ 512; OR¼ 1.30; logistic regression P¼ 0.0024).
The meningitis risk could be mediated through the reduced IgA
and IgG levels.
Discussion
We have identified a previously unknown MM risk locus at 5q15
(ELL2) and a promising MM risk locus at 22q13 (HMGXB4-
TOM1). Neither of these loci has been previously associated with
MM or other lymphoid malignancies. The identified risk variants
are common and their estimated effect sizes are similar to those of
previously identified MM risk variants13–15.
While the mechanisms that promote development of MM
await further exploration, our findings indicate that the ELL2 risk
allele affects plasma cell function. The fact that ELL2 regulates
mRNA processing in plasma cells is compelling, as is the
reduction of IgA and IgG levels associated with the risk allele.
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Figure 3 | The ELL2 haplotype that predisposes for MM is identical to the ELL2 haplotype that influences IgA and IgG levels in healthy subjects.
In addition to the sentinel SNP rs56219066, the association between 5q15 identified in the MM and MMþMGUS meta-analyses was captured by
numerous markers in strong linkage disequilibrium located in aB40-kb haplotype block in ELL2. To verify that the ELL2 haplotype associating with MM and
MMþMGUS is identical to the ELL2 haplotype associating with Ig levels, we tested for association between each available SNP in the ELL2 region and IgA,
IgG and IgM levels using the Icelandic Ig data set. We overlaid the log-linear regression P values for association with Ig levels with the meta-analysis
P values obtained for the same SNPs for association with MM and MMþMGUS: (a) log-linear regression P values for association with IgA (red; left),
IgG (red; middle) and IgM (red; right) overlaid on logistic regression P values for association with MM (blue); (b) corresponding results for MMþMGUS.
The x axes indicate chromosomal positions. The y axes indicate  log10 P values. Sizes of markers reflect degree of association with MM or MMþMGUS.
As shown, all SNPs in theB40-kb haplotype block associating with MM or MMþMGUS associate with IgA and, to a lesser extent, with IgG. We did not
observe any association with IgM. Taken together, ELL2 SNPs associating with MM and MMþMGUS associate with IgA and IgG and vice versa, further
supporting that the ELL2 haplotype that predisposes for MM also influences Ig levels.
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While the altered Ig levels as such are unlikely to be the
MM-predisposing event (as other variants in the Icelandic data
that alter Ig levels do not predispose for MM; not shown), these
changes could reflect a hypomorphic effect on the SEC that affects
mRNA processing broadly, which could predispose for malignant
transformation.
Furthermore, the lower Ig levels could make ELL2 risk allele
carriers susceptible to infections. The potential association with
meningitis is therefore intriguing. While these carriers are
certainly not severely immunodeficient (because the allele is
common), it is well known that various types of limited Ig
deficiency (for example, IgG2 and IgG3 subclass deficiency)
confer an increased incidence of infections, including with
Neisseria meningitidis and other meningitis pathogens. Future
studies will uncover the role of ELL2 in haematological
malignancies and immune response.
Methods
Study populations. For the Swedish-Norwegian discovery sample set, we obtained
1,668 and 157 samples from the Swedish National Myeloma Biobank (Skåne
University Hospital, Lund, Sweden) and the Norwegian Biobank for Myeloma
(Trondheim, Norway), respectively. The samples were banked between 2003 and
2013. In addition, we obtained SNP microarray profiles of population-based
controls from previous studies of twins (n¼ 9835; TWINGENE, http://ki.se/sites/
default/files/twingene_gwas_basic_info.pdf) and schizophrenia31 (n¼ 3,754). From
TWINGENE, we only used one individual from each pair of twins. After this
filtering, a total of 10,704 controls were available for further analysis.
For the Icelandic discovery sample set, we identified from the nationwide
Icelandic Cancer Registry all patients diagnosed with MM (ICD-10 code C90) in
Iceland from 1955 to 2013 were identified and used in the association studies
(n¼ 480). To identify MGUS cases, information on the detection of an M protein
on serum protein electrophoresis was gathered from 1955 to 2005 from Landspitali
University Hospital and the Icelandic Medical Center Laboratory in Mjodd. A total
of 251 cases of non-IgM MGUS were identified and used in the analysis.
For replication, we obtained 223 MM cases from the Swedish National
Myeloma Biobank and 363 MM cases from the University Hospital of Copenhagen.
As controls for the respective replication sets, we used 1,285 randomly ascertained
Swedish blood donors and 826 randomly ascertained individuals from Denmark
and Skåne county, Sweden (the southernmost part of Sweden next to Denmark).
All samples were collected subject to ethical approval (Lund University Ethical
Review Board, 2013/54; Icelandic Data Protection Authority, 2001010157; and
National Bioethics Committee 01/015) and informed consent. No individuals were
approached solely for the purpose of this study.
Analysis of Swedish and Norwegian samples. Samples were genotyped on
Illumina OmniExpress-Exome and OmniExpress microarrays. For analysis, we
used the OmniExpress SNPs, which are recorded by both array types. We excluded
SNPs showing 45% missing data, significant deviation from Hardy–Weinberg
equilibrium (Po1 10 1 in controls; Po1 10 1 in cases), or discrepancies
in allele frequency between genotyping batches (Po5 10 8; w2-test). We
excluded samples showing45% missing data or excess heterozygosity (43 s.d.’s),
and samples from closely related individuals (proportion identity-by-descent
p^40:2; calculated using SNPs with pairwise r2o0.2 using PLINK, after removing
regions of high linkage disequilibrium32,33). After filtering, 542,599 SNPs, 1,714
cases and 10,391 controls remained. Unobserved genotypes were imputed using
phased haplotypes from the Phase I (b37) release of the 1,000 Genomes Project34
(http://www.1000genomes.org). Association testing was performed using logistic
regression under an additive genetic model. To avoid artefacts of cryptic
population stratification, we included five principal components of the identity-by-
state matrix that were found to increase the genomic inflation factor l (ref. 35)
in the regression. The analyses were done with SHAPEIT2 (ref. 36; (https://
mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html), IMPUTE2 (ref. 37;
https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) and SNPTEST38 (https://
mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html).
Analysis of Icelandic samples. Samples were genotyped using Illumina micro-
arrays. The whole genomes of 2,636 Icelanders were sequenced using Illumina
technology to a mean depth of at least 10 (median 20 ), including 909 to a
mean depth of at least 30 (ref. 39). A total of 35.5 million autosomal SNPs and
indels were identified using the Genome Analysis Toolkit version 2.3.9 (ref. 40).
We used information about haplotype sharing to improve variant genotyping,
taking advantage of the fact that all sequenced individuals had also been chip-typed
and long-range phased17. Variants were annotated using Ensembl release 72 and
Variant Effect Predictor (VEP) version 2.8 (ref. 41). The 35.5 million sequence
variants found and genotyped by whole-genome sequencing were then imputed
into 104,220 Icelanders who had been genotyped using Illumina chips. In addition,
using the Icelandic genealogy, we calculated genotype probabilities for 294,212
untyped individuals who are close relatives of the chip-typed individuals born after
1880 (Gudbjartsson et al. 39). Including this increases the power to detect
associations with all diseases where ungenotyped cases are available. Logistic
regression was used to test for association between SNPs and disease, treating
disease status as the response and genotype counts as covariates. Other available
individual characteristics that correlate with disease status were also included in the
model as nuisance variables. These characteristics were as follows: sex, county of
birth, current age or age at death (first and second order terms included), blood
sample availability for the individual and an indicator function for the overlap of
the lifetime of the individual with the time span of phenotype collection (described
in detail below). The control set selected for each case group can thus be different
after matching for the nuisance variables (Gudbjartsson et al. 39). Correction for
familial relatedness was carried out using the method of genomic control by
dividing the corresponding w2-statistic by 1.04 and 1.02 for MM and
MMþMGUS, respectively.
Meta-analysis. We performed association testing in each discovery set separately
and combined the results for 12.1 million variants that were shared by the Icelandic
and 1,000 Genomes whole-genome sequencing data. These variants passed the
quality thresholds applied: minor allele frequency40.1%, imputation information
value 40.8 and consistent frequency between the two sample sets. The meta-
analysis was done using METAL42 (http://www.sph.umich.edu/csg/abecasis/metal)
with a fixed effect model. Conditional association analysis with respect to
rs56219066 and rs138740 using SNPTEST38 did not reveal any other underlying,
independent signals.
Gene expression analysis in haematopoietic cell types. To characterize gene
expression patterns of ELL2, TOM1 and HMGXB4, we used microarray data from
the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo). These data
included gene expression profiles of different types of blood cells from normal
haematopoiesis (n¼ 211; accession no. GSE24759 (ref. 43)), plasma cells from
patients with MM (n¼ 1,285; accession nos. GSE15695 (ref. 44) GSE4581,
GSE19784 (ref. 45) and GSE26760 (ref. 46)), and plasma cells from patients with
MGUS, patients with smouldering MM and healthy bone marrow donors (n¼ 78;
accession no. GSE5900 (ref. 47)). All data were generated on Affymetrix U133A
and Av2 microarrays and quantile-normalized to a log-normal distribution.
Genotyping and association analysis of replication samples. The Swedish and
Danish replication samples were genotyped by quantitative PCR for ELL2
rs56219066 (Taqman custom assay AHCTDL6), ELL2 rs3815768 (Taqman assay
C_22272652_30) and TOM1 rs138726 (D0/r2¼ 1/0.997 with rs138740; Fluidigm
SNP type assay GTA0072445). Association analysis for the replication sets was
done using NEMO48 assuming a multiplicative risk model. Results for the
discovery and replication cohorts were combined using a Mantel–Haenszel fixed
effect model. Heterogeneity in the effect estimate was tested assuming that the
estimated ORs for different groups followed a log-normal distribution using a
likelihood ratio w2-test with degrees of freedom equal to number of groups
compared minus one.
Association of the risk alleles with gene expression. To test for associations
between identified risk variants and the expression of nearby genes, we analysed
SNP and gene expression microarray data generated from peripheral blood samples
(eight data sets totalling 973 individuals from the Icelandic population49 and 8,086
individuals of other European populations50) and lymphoblastoid cell lines
(two data sets totalling 1,188 samples51,52). Gene expression in the Icelandic data
set was quantified as the mean log10 expression ratio compared with pooled
reference RNA samples, and regressed against the number of risk alleles carried,
age, gender, relatedness and differential white blood cell counts.
Association of ELL2 allele with Ig levels. To screen for associations between
the identified MM risk allele at ELL2 and Ig levels, we used IgA, IgG and IgM
measurements from 24,279, 21,981 and 20,413 individuals from the Icelandic
population, respectively. Subjects diagnosed with MM or MGUS were not included
in this data set. Ig levels adjusted for age, sex and site were tested for association
with imputed genotypes using generalized log-linear regression16. Individuals
diagnosed with MM or MGUS were excluded. In addition, we used IgA, IgG
and IgM data from 1,012 Swedish blood donors (Clinical Immunology and
Transfusion Medicine, Lund, Sweden) previously genotyped for ELL2 rs17085249
(D0/r2¼ 1/0.957 with rs56219066 and D0/r2¼ 1/1 with rs3815768, Fluidigm SNP
type assay GTA0072447). For the latter samples, we used Pearson correlation for
association testing. All Ig measurements were done at certified clinical laboratories
in Iceland and Sweden.
Association of the ELL2 risk allele with other traits. The deCODE Genetics
phenotype database contains medical information on diseases and traits obtained
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through collaboration with specialists in each field. This includes information on
cardiovascular diseases (myocardial infarction, coronary arterial disease, peripheral
arterial disease, atrial fibrillation, sick sinus syndrome and stroke), metabolic
disorders (obesity, diabetes and metabolic syndrome), psychiatric disorders
(schizophrenia, bipolar disorder, anxiety and depression), addictions (nicotine
and alcohol), inflammatory diseases (rheumatoid arthritis, lupus and asthma),
musculoskeletal disorders (osteoarthritis, osteoporosis), eye diseases (glaucoma),
kidney diseases (kidney stones and kidney failure) and 29 types of cancer.
Anthropometric measures have also been collected through several of these
projects. Routinely measured traits from patient workups (sodium, potassium,
bicarbonate, calcium, phosphate, creatinine, blood cell counts, haemoglobin,
haematocrit, Igs, iron, vitamins, lipids and more) were obtained from the
Landspitali University Hospital, Reykjavik, and the Icelandic Medical Center
Laboratory in Mjodd (Laeknasetrid), Reykjavik, in addition to more specific
hormonal measures (adrenal, thyroid and sex hormones). The number of
independent and uncorrelated secondary traits tested for association with
rs56219066 amounts to 400.
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